Pharma BD Deal Intelligence
Vascugel was shelved in 2014 after unexpected trial complications, and Shire exited the whole Regenerative Medicine unit it belonged to within two years of the Pervasis deal.
Full analysis, sources & comparables →Shire's Pervasis acquisition added Vascugel and an endothelial cell platform to its regenerative medicine division alongside Dermagraft, with deal value up to…
Shire to purchase substantially all Pervasis Therapeutics assets to fortify its regenerative medicine business, gaining the Vascugel platform to reestablish…
Shire initiated two Phase 2 studies of SRM003/Vascugel in ESRD patients undergoing AV access creation for hemodialysis — confirming the asset advanced into…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Shire acquired substantially all Pervasis Therapeutics assets for an undisclosed upfront plus milestone payments totaling up to ~$200M. Added Phase 2 Vascugel cell-based vascular access therapy to Shire's regenerative medicine business (alongside Dermagraft from 2011 Advanced BioHealing deal).
Vascugel was shelved in 2014 after unexpected trial complications, and Shire exited the whole Regenerative Medicine unit it belonged to within two years of the Pervasis deal.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Pervasis Therapeutics, Inc. (this deal) | 2012 | $200M | 18 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
← Browse all deals · How we score deals
More: 2012 deals · Shire plc deals · Nephrology deals